Solid Tumor Clinical Trials in New York, New York

33 studies are recruiting for solid tumor in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

   The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   New York Presbyterian Hospital, New York, New York

   Locations

   15 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06401356 on ClinicalTrials.gov

2. A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

   The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer [OC], endometrial cancer [EC], non-sma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   58 in total

   Run by

   Eisai Inc.

   See if you can join NCT04300556 on ClinicalTrials.gov

3. Brodalumab in the Treatment of Immune-Related Adverse Events

   The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University Irving Medical Center, New York, New York

   Run by

   Brian Henick, MD

   See if you can join NCT06673329 on ClinicalTrials.gov

4. A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

   This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Site 0173, New York, New York

   Locations

   24 in total

   Run by

   K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

   See if you can join NCT04516447 on ClinicalTrials.gov

5. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

   This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Langone, New York, New York

   Locations

   21 in total

   Run by

   I-Mab Biopharma US Limited

   See if you can join NCT04900818 on ClinicalTrials.gov

6. A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

   This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Cancer Institute Clinical Cancer Center, New York, New York

   Locations

   15 in total

   Run by

   OnCusp Therapeutics, Inc.

   See if you can join NCT06234423 on ClinicalTrials.gov

7. Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

   The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to targ…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University Medical Center, New York, New York

   Locations

   27 in total

   Run by

   Oxford BioTherapeutics Ltd

   See if you can join NCT04064359 on ClinicalTrials.gov

8. Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

   This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mount Sinai, New York, New York

   Locations

   8 in total

   Run by

   Impact Therapeutics, Inc.

   See if you can join NCT05269316 on ClinicalTrials.gov